Back to Single Peptide Protocols
Single PeptideLongevity & Mitochondrial5 mg vialOnce dailySubcutaneousMitochondrial
SS-31 / Elamipretide (5 mg Vial) Dosage Protocol
SS-31 (Elamipretide) dosage protocol for the 5 mg vial. Mitochondria-targeted tetrapeptide for cardioprotection and longevity research.
Vial Size
5 mg
Route
Subcutaneous
Frequency
Once daily
Dose Range
0.1–0.5 mg/day
Dosage Schedule
| Period | Dose |
|---|---|
| Weeks 1–2 (starter) | 0.1 mg/day |
| Weeks 3+ (maintenance) | 0.25–0.5 mg/day |
Route: Subcutaneous · Frequency: Once daily · Cycle: 4–12 weeks
How It Works
SS-31 (Elamipretide) is a mitochondria-targeted tetrapeptide that selectively concentrates in the inner mitochondrial membrane, protecting cardiolipin and restoring ATP synthesis. It has shown cardioprotective effects in multiple clinical trials.
Potential Benefits
- •Cardioprotective effects in clinical trials (EMBRACE-HF).
- •Restores mitochondrial function and ATP production.
- •Reduces oxidative stress.
- •Potential longevity and anti-aging applications.
Side Effects & Risks
- •Injection-site reactions (most common in trials).
- •Generally well-tolerated in clinical studies.
Important Notes
- In clinical development for heart failure (Stealth BioTherapeutics).
- Research-use only; not FDA-approved.
Storage Instructions
- Lyophilized: −20 °C (−4 °F).
- Once mixed: 2–8 °C; use within 7 days.
References
- [1]Daubert MA et al. Novel Mitochondria-Targeting Peptide in Heart Failure Treatment. JACC Heart Fail 2017.View Source
- [2]Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. Br J Pharmacol 2014.View Source
Research & Educational Use Only: This protocol is for educational and research purposes only. It does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before making any decisions related to peptides or any other compounds.